Mont-Saint-Guibert, Belgium Celyad (Euronext Brussels and Paris, and NASDAQ : CYAD), the biopharmaceutical company, belgian leader in the development of cell therapies, today announced the issuance of u.s. patent no. 9.663.763 bearing on the method of treatment of cancer of Celyad by the administration of human T cells and allogeneic primary developed to become deficient in TCR (T-Cell Receptor) and express an antigen receptor chimeric (BECAUSE).
Download the free guide
Boost your gains
The u.s. patent 9.663.763, examined in the framework of the pilot program of immunotherapy and oncology also known as theinitiative ” Patents 4 Patients “, is the third patent portfolio of intellectual property allogeneic Celyad granted by the u.s. patent Office (United States Patent and Trademark Office – USPTO). This new patent focuses more on the methods of treatment of cancer patients using immunotherapy in allogeneic cell-based AS-T deficient in TCR. Earlier patents related to the cells in allogeneic CAR-T deficient in TCR, as such, certain methods of production. The combination of all the patents granted therefore strengthens the position of Celyad and confirms its leadership in the development of cellular therapies and in the field BECAUSE-T allogeneic.
The technology allogenic has the potential to broaden the therapeutic applications of immunotherapies based on cells CAR-T to the extent that it does not depend on cells derived from the patient. Cells CAR-T-deficient TCR are intended to avoid or significantly reduce the immune reactions adverse drug reactions (such as graft-versus-host – [GVHD]), which would be enormously beneficial to patients.
Dr Christian Homsy, CEO of Celyad, said : “We are delighted to have been awarded this new patent. This is in addition to other u.s. patents which have been granted previously and reinforces our strong position in the field of intellectual property in the field BECAUSE-T. We are expanding our portfolio of patent that covers the essential aspects of the value chain allogeneic cell production CAR-T deficient in TCR. ”
Dr. Georges Rawadi, Vice-President of Business Development and Intellectual Property Celyad : “The cells CAR-T and allogeneic increasingly attract the interest of many pharmaceutical companies and biopharmaceutical involved in immunotherapeutics cell against cancer. We seek to maximize the significant value of our assets BECAUSE, allogeneic T through collaborations and strategic partnerships such as those we have entered into with ONO Pharma, and Novartis. ”
About Celyad
Celyad is a company’s clinical-stage biopharmaceutical in the development of cellular therapies. The Company uses its expertise in cellular development to target the cancer. The platform NKR-T Celyad is based on T-Cell changes in order to push them to express a Receptor of Natural Killer Cells (NK). This technology offers a potential therapeutic very wide, both in solid tumors than in the blood. BECAUSE-T NKR-2 is the product most advanced candidate of Celyad in oncology. This therapy has been the subject of a first clinical study of Phase I study to evaluate the safety of the product in patients with two types of blood cancer, Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM), This study was successfully completed in September 2016. Celyad was founded in 2007. The Company is based in Mont-Saint-Guibert, Belgium, and Boston, in the United States. The actions of Celyad are listed on Euronext Brussels and Euronext Paris under the symbol CYAD. The ADSS are quoted on the NASDAQ Global Select Market under the symbol ” CYAD “.
For more information on Celyad, go on www.celyad.com
Download the free guide
Boost your gains
